Oura Ring Gen 4 sensor data — not clinical measurementsN=1 case study — not validated for clinical decisionsHEV diagnosed Mar 18; interpret findings cautiously in this Day 72 post-ruxolitinib window

Full Biometric Analysis

Wearable-derived biometric summary for the current observation window
Generated 2026-05-28 07:28
RMSSD
Low
16.7ms
Normal: 36-72 ms
Sleep HR
Normal
79.7bpm
Normal range
HRV Balance
Low
58/100
Oura readiness contributor
Readiness
Normal
69/100
30-day average
Sleep Score
Normal
67/100
25/130 days <60
Daily Steps
Low
3256
61 days <2000
Vascular Age
Info
0yr
Oura estimate across 0 days
SpO2
Normal
96.1%
Lowest: 93.4%

HRV Deep Dive

RMSSD Comparison

Heart Rate

Sleep

Readiness & Recovery

Resilience & Vascular Age

SpO2 & Stress

Activity

Clinical Summary

This summary describes the wearable signals observed in the current data window. It does not assert specific clinical history or diagnosis. Mean RMSSD is 16.7 ms, 66% below the reference median (49 ms).
RMSSD (HRV) 66% below median
16.7 ms
080 ms
Normal: 36-72 ms (P25-P75)
Sleep HR Borderline
80 bpm
40110 bpm
Normal sleep HR: 50-65 bpm
HRV Balance Critically low
58 /100
0100
Normal: 50-80 (Oura readiness component)
Daily Steps 3,256 avg
3,256 steps
010,000
Normal: 5,000-8,000 steps/day
Sleep Moderate
Score 67/100
Duration 6.3 hrs
Poor days 25/130
Sleep HRV 16 ms
Physical Capacity Severe
Activity score 57/100
Days <2k steps 61
Resilience Variable
SpO2 Low Normal
Average 96.1%
Lowest 93.4%
BOS risk Borderline
Vascular Age Estimate Estimate
Mean estimate 0 yr
Observed range 0-0 yr
Available days 0
10,812
RMSSD samples
over 136 days
66%
below reference
median
0 yr
mean vascular age
estimate
Wearable-derived snapshot for this observation window: RMSSD averages 16.7 ms, sleep heart rate is borderline, activity averages 3,256 steps/day, and the Oura vascular age estimate averages 0 yr. These are descriptive wearable outputs only, not confirmed diagnoses or verified medical history.
References (4)
  1. Kleiger RE et al. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987;59:256-62
  2. Bigger JT et al. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 1992;85:164-71
  3. Shaffer F, Ginsberg JP. An Overview of HRV Metrics and Norms. Front Public Health 2017;5:258
  4. Nunan D et al. Normal values for short-term HRV. Pacing Clin Electrophysiol 2010;33:1407-17